Loading data for OLMA — first visit, this takes a few seconds.

アラート

Olema Pharmaceuticals Inc... (OLMA)

NasdaqGS: OLMA · リアルタイム株価 · USD

10.93

+0.28 (2.63%)

終値時点： Aug 18, 2026, 3:59 PM

2.63% (1D)

買気配	8.05
時価総額	951.1M
売上高（TTM）	n/a
純利益（TTM）	-204.57M
ベータ	2.01
EPS（TTM）	-2.12
PER（TTM）	n/a
予想PER	-4.04
PBR（TTM）	2.21
PSR（TTM）	n/a
Earnings Date	Nov 9, 2026

売気配	14.06
出来高	810,817
平均出来高（20日）	1,424,543
始値	10.90
前日終値	10.65
当日レンジ	10.85 - 11.32
52週レンジ	5.34 - 36.26
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

OLMAについて

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative ...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Nov 19, 2020

従業員数 150

上場取引所 NasdaqGS

ティッカー OLMA

ウェブサイト https://olema.com

企業情報の全文

業績

2025年のOlema Pharmaceuticalsの売上高は0で、前年の0からundefined%の増加でした。利益は-162.45Mで、25.47%の増加でした。

財務諸表

決算サプライズ

Olema PharmaceuticalsはAug 10, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.

EPSは -0.61 で、予想を下回りました -0.05, うち -19.61% の前年比減少.

次回決算発表

Olema Pharmaceuticals Inc.の決算発表予定日は Nov 9, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1か月前 · Simply Wall St.

Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?

In June 2026, Olema Pharmaceuticals, Inc. was added to multiple Russell growth benchmarks, including the Russell 2000 Growth, 2500 Growth, 3000 Growth, 3000E Growth, Small Cap Comp Growth, and Microca...

2か月前 · Insider Monkey

How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the small-cap stocks with potential to rise 1000 percent. The company gave investors a new pipeline marker on May 21, when it reported initial Phase...

2か月前 · Simply Wall St.

Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap

Olema Pharmaceuticals (NasdaqGS:OLMA) reported preliminary Phase 1 data for oral KAT6 inhibitor OP-3136, showing anti-tumor activity in multiple advanced solid tumors. The early readout highlighted tu...

2か月前 · Stocktwits

Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study

Early ASCO data for OP-3136 pointed to encouraging anti-cancer activity with a clean safety profile, adding momentum to OLMA’s pipeline story.

3か月前 · Simply Wall St.

Assessing Olema Pharmaceuticals (OLMA) Valuation After Adding Dr. Prakash Raman To The Board

Olema Pharmaceuticals (OLMA) has drawn fresh attention after appointing Prakash Raman, Ph.D., to its Board of Directors. This move puts an experienced oncology and immunology dealmaker closer to the c...

2ページ中1ページ

Olema Pharmaceuticals Inc... (OLMA)